No se publicó un resumen junto con este documento; las guías de sociedades, las vías de consenso y las declaraciones científicas suelen difundirse sin él. Consulte los Puntos Clave y el PDF enlazado para ver el contenido completo.
“Our thinking about this disease has evolved. We now better understand the interplay of risk factors involved in both the progression of the disease and the occurrence of adverse events such as heart attack and cardiac death. With this new guideline, we have transitioned from arbitrarily picking and choosing individual therapies to recognizing there is a package of lifestyle modifications and medications—what we call guideline-directed medical therapy—that benefits most patients.”
Fihn et al. (Mon,) studied this question.